Review
Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer
- PMID: 33757114
Item in Clipboard
Review
Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer
Med Lett Drugs Ther.
.
No abstract available
Keywords: Adriamycin; Halaven; Lynparza; Talzenna; Taxol; Tecentriq; Trodelvy; adverse effects; atezolizumab; breast cancer; capecitabine; dosage; doxorubicin; drug interactions; efficacy; eribulin; fluorouracil; gemcitabine; irinotecan; lactation; olaparib; paclitaxel; pregnancy; sacituzumab govitecan; safety; talazoparib; vinorelbine.
Similar articles
-
Sacituzumab govitecan activity in advanced breast cancer.Lancet Oncol. 2017 May;18(5):e246. doi: 10.1016/S1470-2045(17)30232-2. Epub 2017 Mar 23. Lancet Oncol. 2017. PMID: 28343977 No abstract available.
-
Sacituzumab govitecan-hziy for triple-negative breast cancer.Lancet Oncol. 2019 Apr;20(4):e194. doi: 10.1016/S1470-2045(19)30074-9. Epub 2019 Feb 28. Lancet Oncol. 2019. PMID: 30827748 No abstract available.
-
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
-
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.Expert Rev Anticancer Ther. 2019 Aug;19(8):673-679. doi: 10.1080/14737140.2019.1654378. Epub 2019 Aug 19. Expert Rev Anticancer Ther. 2019. PMID: 31398063 Review.
-
Sacituzumab Govitecan: First Approval.Drugs. 2020 Jul;80(10):1019-1025. doi: 10.1007/s40265-020-01337-5. Drugs. 2020. PMID: 32529410 Free PMC article. Review.
Cited by
-
The expression and role of the Lem-D proteins Ankle2, Emerin, Lemd2, and TMPO in triple-negative breast cancer cell growth.Front Oncol. 2024 Apr 24;14:1222698. doi: 10.3389/fonc.2024.1222698. eCollection 2024. Front Oncol. 2024. PMID: 38720803 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
